Regulatory MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority Pharmaceutical TechnologyMSD and Daiichi Sankyo have received priority review from the FDA for ifinatamab deruxtecan's BLA to treat ES-SCLC.RegulatoryOncologyRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) Pharmaceutical Technology MSD and Daiichi Sankyo have received priority review from the FDA for ifinatamab deruxtecan’s BLA to treat ES-SCLC. RegulatoryOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Alamar, Hemab, Kailera, and Seaport advance IPOsNext: Revolution rockets on strong pancreatic cancer data Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
